Answers are grounded in this paper and cite their sources.
BACKGROUND Azelastine, a widely used H1-antihistamine with demonstrated antiviral and antiinflammatory activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in preclinical and early clinical studies, has emerged as a potential repurposed therapy for early infection.This systematic review and meta-analysis aimed to evaluate the efficacy and safety of intranasal azelastine for the treatment of established SARS-CoV-2 infection and the prevention of incident SARS-CoV-2 infection.AIM To systematically evaluate the randomized evidence on intranasal azelastine for the treatment of established SARS-CoV-2 infection and the prevention of incident SARS-CoV-2 infection, with particular emphasis on virological outcomes, prevention efficacy, and safety.METHODS PubMed/MEDLINE, EMBASE, and Cochrane Library, together with trial registries and preprint servers, were searched through January 16, 2026.Randomized controlled trials evaluating intranasal azelastine vs placebo were identified through January 2026.Treatment efficacy was assessed using changes in SARS-CoV-2 viral load at predefined follow-up time points, while prevention efficacy was assessed using incident polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection.Safety outcomes were synthesized separately.Risk of bias was assessed using RoB-2 and certainty using Grading of Recommendations Assessment, Development and Evaluation.Randomeffects meta-analysis was used where quantitative pooling was appropriate. RESULTS / 45Three randomized controlled trials involving 754 participants were included.Two treatment trials contributed to the viral-load analyses, while one prevention trial evaluated incident SARS-CoV-2 infection.Among the two treatment trials, moderatecertainty evidence suggested a greater reduction in SARS-CoV-2 viral load at day 3 [mean difference (MD): -0.18, 95% confidence interval (CI): -0.25 to -0.12; I² = 0%].The difference was smaller at day 5/6 (MD: -0.11, 95%CI: -0.18 to -0.05; I² = 0%) and was not statistically significant at day 11 (MD: -0.09, 95%CI: -0.26 to 0.07; I² = 4%).In the prevention trial, PCR-confirmed SARS-CoV-2 infection occurred in 5/227 participants (2.2%) receiving azelastine vs 15/223 (6.7%) receiving placebo [risk ratio (RR): 0.33, 95%CI: 0.12-0.89].Treatment-only all-adverse event pooling showed RR 0.85 (95%CI: 0.56-1.27;I² = 61%), whereas the prevention trial showed RR 2.25 (95%CI: 1.64-3.09). CONCLUSIONModerate-certainty evidence suggested an early virological difference with intranasal azelastine in established SARS-CoV-2 infection, particularly at day 3, although the clinical relevance of this surrogate outcome remains uncertain.Evidence for prevention was based on a single randomized trial, while safety findings differed between treatment and prevention populations.Overall, the available evidence is exploratory and insufficient to establish clinical benefit on patient-important outcomes.
No takes yet. Share an insight, caveat, or question.
Rath et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: